the tape · 2026-09-01GPRO▲ +40.4%DELL▼ -6.8%COIN▼ -6.0%ASTS▼ -5.6%ORCL▼ -5.2%HPQ▲ +4.3%FCX▼ -4.3%AMAT▼ -3.6%PLTR▼ -3.5%TSLA▼ -3.2%ARM▼ -2.9%COP▲ +2.8%NEM▼ -2.7%TMO▼ -2.7%MU▼ -2.6%AAPL▲ +2.6%HD▼ -2.5%CVX▲ +2.4%AMD▼ -2.4%CAT▼ -2.3%
Video · 2026-09-01
ORCL down 5.2% on Cowen target cut
The catalyst: Cowen target cut.
Oracle (ORCL) is back in focus after Oracle Health rolled out new Clinical AI Agent features in the U.S., extending automation across documentation, coding, and chart review workflows inside electronic health records. Despite the new Oracle Health AI features and large cloud and AI contracts, Oracle’s share price is still down 23.81% year to date and the 1 year total shareholder return is down 33.
As reported: “Oracle (ORCL) Could Be 23% Undervalued On Its Cloud And AI Narrative” — Yahoo Finance, 2026-09-01.
What happened after
T+1 — pendingT+5 — pendingT+20 — pending
More: ORCL move history · track record · that day's brief · watch on YouTube
The brief, in your inbox
One email every market morning. What moved, why, and what happened after.